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1 B.M. and M.V. were principal investigators.Leptin is an adipocyte-derived hormone/cytokine that modulates immune responses. It induces
functional and morphological changes in human dendritic cells (DCs), licensing them towards
Th1 priming and promoting DC survival. Here we found that leptin protects DCs from spontaneous,
UVB and H2O2-induced apoptosis, by triggering the activation of nuclear factor-kappa B (NF-kB) and
a parallel up-regulation of bcl-2 and bcl-XL gene expression and Akt activation. We found that leptin
activates the PI3K-Akt signaling pathway as demonstrated by the suppression of the effect of leptin
on DC survival by wortmannin and API-2, which suppress the leptin-induced activation of Akt, NF-
kB, bcl-2, bcl-XL and protection from apoptosis. These results provide insights on the immunoreg-
ulatory function of leptin, supporting a potential application in immunotherapeutic approaches.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Leptin, the product of obese (ob) gene, is a non-glycosylated
protein, mainly secreted by adipocytes. Structurally, leptin is a
member of the helical cytokine family which includes Interleukin
(IL)-6, IL-11, IL-12, G-CSF [1]. Leptin is released into the circulation,
and its plasma level correlates with total body fat mass and
changes in energy balance [2], and is dynamically regulated, being
reduced by fasting [3] and raised by inﬂammatory mediators such
as IL-1 and LPS [4].
Several in vitro studies have demonstrated that leptin acts di-
rectly on its receptor Ob-R, and only the long isoform (Ob-Rb) is
thought to be of prime importance in leptin signaling which in-
volves the Janus kinase (JAK)-signal trasducers and activator of
transcription (STAT) pathway as for the majority of cytokines [5].
Leptin receptor is expressed at highest relative density in the hypo-
thalamus but also in peripheral tissues and in different cell popu-
lations of the immune system as T cells [6], natural killer (NK) cells
[7], monocytes–macrophages [8], DCs [9] and B cells [10].
Leptin has been shown to inﬂuence CD4+ T lymphocyte prolifer-
ation and cytokine secretion, shifting immune responses toward
the Th1 phenotype and suppressing Th2 responses [6]. It has beenchemical Societies. Published by E
activated protein kinase; NF-
sitol 3-kinase; STAT, signalshown that leptin has an immunomodulatory role on NK cells [7],
neutrophils [11], macrophages [8], and monocytes [12] function,
acting as a proinﬂammatory signal and inducing activation and
TNF-a and IL-6 production.
DCs are the most potent antigen presenting cells and play a cru-
cial role in the generation and regulation of immunity [13]. Their
priming ability is acquired upon maturation and is characterized
by the activation of different transcriptional factors, leading to
the modulation of genes involved in cytoskeleton rearrangement,
antigen processing, control of migration and regulation of inﬂam-
matory responses [14].
We have previously demonstrated that leptin oversees DC
developmental program inducing a coordinate series of functional
and morphological changes in these cells making them more com-
petent APC, licensing them towards Th1 priming and increasing
their capacity to stimulate activation of autologous CD8+ T cells
[9,15]. Moreover, we found that leptin increases immature DC
(iDC) migratory performance by favouring cytoskeleton dynamics
and by up-regulating CCR7, thus favouring chemotactic respon-
siveness [15].
Leptin has been shown to exert anti-apoptotic activity in T
cells [16], monocytes [17], neuroblastoma cells [18], neutrophils
[19], hippocampal neurons [20] and murine DCs [21], while
inducing apoptosis in human bone marrow (BM) stromal cells
[22]. The reason for these contrasting responses in different cell
types is unclear, but differences in the expression patterns of
leptin receptors and associated signaling molecules may play a
role.lsevier B.V. All rights reserved.
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survival [9] and partially protects them from spontaneous and
UVB-induced apoptosis. Therefore, this study was designed to
investigate the mechanism by which leptin acts as an anti-apopto-
tic signal on DCs.
2. Materials and methods
2.1. Leptin
Human recombinant leptin was purchased from R&D System. A
dose–response titration curve was performed to assess the optimal
leptin concentration. Leptin was added at the beginning of the cul-
ture period and left throughout at the concentration of 10 nM. This
dose gives an optimal stimulation and falls into the range of human
serum levels. Endotoxin levels were <0.03 endotoxin units/ml as
assessed by Limulus assay (BioWhittaker).
2.2. Cell culture
PBMC were isolated by Ficoll-Hypaque (Flow Laboratories) gra-
dient separation of buffy coats obtained from healthy volunteer
blood donors by the Transfusion Center of University of Rome.
DCs were generated as previously described [9]. Untreated iDCs
were used as controls. After 5 days of culture, leptin and/or
200 ng/ml LPS (Escherichia coli serotype 0111:B4, Sigma), were
added to immature DCs. In some experiments, DC were pre incu-
bated for 30 min with 100 ng/ml wortmannin (Alexis Biochemi-
cals, San Diego, CA) or 20 lM of API-2 (Calbiochem, San Diego, CA).
2.3. Flow cytometry
Intracellular staining of P-Akt was performed using the BD
Cytoﬁx Cytoperm Plus Kit (Becton Dickinson Biosciences) and a
rabbit polyclonal anti-P-Akt antibody (Santa Cruz Biotechnology,
San Diego, CA).
2.4. Reverse transcriptase-polymerase-chain reaction (RT-PCR)
RT-PCR for detection of mRNA expression of GAPDH, Bcl-2 and
Bcl-xL was performed as previously described [9].
2.5. Nuclear factor-kappa B (NF-kB) activation assay
To monitor NF-kB activation, we used the NF-kB p65/NFkB p50
transcription factor assay Kits (Alexis Biochemicals), as previously
described [9].
2.6. UVB exposure and H2O2 treatment
For apoptosis induction, untreated and leptin or LPS-treated DCs
were exposed either to H2O2 0.3 mM (Merck & Co., Whitehouse Sta-
tion, NJ, USA) or to UVB (1200 J/m2) as previously described [9].
Leptin or LPS treatment was performed 30 min before and during
H2O2 or UVB exposure, and for the following 24 h.2.7. Apoptosis detection
FITC-Annexin V/Propidium Iodure (PI) double staining was used
to detect apoptosis. Untreated and leptin or LPS-treated DCs were
harvested and washed twice with ice cold PBS and speciﬁc binding
of FITC-annexin V and staining with PI was performed with an
apoptosis detection kit (Pharmingen) accordingly to the manufac-
turer’s instructions. The cells were then analyzed by ﬂow
cytometry.2.8. Western blot
For detection of Akt, P-Akt and actin levels, control or treated
cells were lysed, and protein concentration was calculated using
the DC Protein Assay (Bio-Rad). Sample were loaded on 8% SDS–
PAGE and analyzed by western blot using anti-Akt, anti-P-Akt or
anti-actin pAb (Santa Cruz). Immunoreactive bands were visual-
ized using a secondary horseradish-peroxidase-conjugated anti-
rabbit or anti-mouse pAb and the Western Blot Detection Kit,
Chemioluminescent system (Upstate, Lake Placid, NY).2.9. Data analysis and statistics
Statistical analysis was calculated using a two-tailed Student’s t
test. A P value of less than 0.05 was considered as statistically
signiﬁcant.
3. Results and discussion
We have previously demonstrated that leptin promotes DC sur-
vival [9] up-regulating anti-apoptotic gene expression. This anti-
apoptotic role of leptin has been shown in different cell types
[16–22], but the mechanisms underlying these effects are still con-
troversial. For this reason, we investigated on the survival pathway
activated by leptin in human iDC in our in vitro system.
As shown in Fig. 1A, and in part already demonstrated [9], leptin
partially protect iDC from spontaneous apoptosis and from UVB
and H2O2-induced apoptosis: iDCs were left untreated or were
treated with leptin or LPS for 24 h, and quantitative evaluation of
apoptosis was performed by ﬂow cytometry by double staining
with PI and annexin V. Leptin signiﬁcantly reduces the percentage
of annexin V+/PI (early apoptosis) in leptin-treated iDC after 24 h,
compared to untreated or LPS-treated iDCs. Moreover, as shown in
Fig. 1A, leptin treatment is effective also after apoptosis induction
by UVB or H2O2 exposition. In LPS-treated DCs leptin exerted a
weaker anti-apoptotic effect (data not shown) and we therefore
performed next our experiments on iDCs.
Consistent with the observed anti-apoptotic effect of leptin we
had previously [9] demonstrated the up-regulation of bcl-2 and
bcl-xL mRNA levels after 24 h of leptin treatment as determined
by PCR (Fig. 1B), and an up-regulation of NF-kB p50 and p65 sub-
units after 30 min treatment (Fig. 1C).
One of the pathways that lead to the activation of NF-kB and
that could be involved in the leptin-dependent cell survival, is
the PI3K-Akt. Akt signaling inactivates several pro-apoptotic fac-
tors, but also activates transcription factors that up-regulate anti-
apoptotic genes like bcl-2. Moreover, Lam et al. demonstrated that
leptin activates Akt in murine DC [23]. To determine if this is the
anti-apoptotic signaling pathway exploited by leptin in human
iDCs, we evaluated its ability to induce Akt phosphorylation and
activation.
Akt phosphorylation was evaluated by ﬂow cytometry and we
found that an increase in Akt phosphorylation is readily detectable
after 10 min of leptin treatment, reaching a peak after 30 min/1 h
(Fig. 2) and decreasing to control levels after 4 h (data not shown).
As a positive control we evaluated Akt activation LPS-induced, and
as expected we observed a signiﬁcant increase in Akt phosphoryla-
tion detectable after 20 min of LPS treatment, and a decrease to
control levels after 1 h.
In light of these results we intended to demonstrate that leptin
acts as a survival factor for human iDCs through the activation of
PI3K-Akt pathway. To this aim we veriﬁed whether the inhibition
of PI3K by wortmannin, could suppress the leptin effects on DC
survival (wortmannin treatment was performed for 30 min before
leptin addition). Moreover we tested also the Akt/PKB Signaling
Fig. 1. Leptin protects DCs from spontaneous and induced apoptosis and induces bcl-2 and bcl-xL expression and activates NF-kB in DCs. (A) DCs were left untreated (CTR) or
treated for 24 h with leptin or LPS, and quantitative evaluation of apoptosis was performed by ﬂow cytometry by double staining with PI and annexin V+. The second and third
set of histograms refer to induced apoptosis: DCs were exposed to UVB (1200 J/m2) from a Philips TL 20W/12 lamp, or to H2O2 0.3 mM. Leptin and LPS treatment were
performed 30 min before and during H2O2 incubation or UVB exposure, and for the following 24 h. The histograms show means ± S.E.M. from four different experiments.
*P < 0.05. (B and C) DCs were left untreated (CTR) or treated with leptin or LPS for 30 min or 24 h. (B) After 24 h treatment the levels of bcl-2 and bcl-xL mRNA were
determined by semiquantitative RT-PCR. Results are expressed as fold induction (F.I.) over the basal level of untreated DCs. Representative results from one of four donors
giving similar results are shown. (C) After 30 min of treatment cells were lysed and, after protein content quantiﬁcation, equal amounts of lysates were used to test activated
levels of both p50 and p65 subunits of NF-kB for each sample. As positive control HeLa cell extract was used, alone or in presence of WT or mutated (MUT) consensus
oligonucleotide (data not shown). Mean values ± S.E.M. from three different donors are shown. *P < 0.05.
Fig. 2. Leptin up-regulates Akt phosphorylation. DCs were left untreated (CTR) or
treated with leptin or LPS for 10 min, 20 min, 30 min, 1 h. Akt phosphorylation was
evaluated by ﬂow cytometry. Intracellular staining was performed using the BD
Cytoﬁx Cytoperm Plus Kit (Becton Dickinson Biosciences) and using a rabbit
polyclonal anti-P-Akt antibody (Santa Cruz Biotechnology). Results are expressed as
mean ﬂuorescence intensity (MFI). Mean values ± S.E.M. from three different donors
are shown. *P < 0.05.
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lation of Akt by targeting an Akt effector molecule other than PI3K.
This inhibitor exhibits little effect towards cellular signaling path-
ways mediated by PKC, PKA, SGK, Stat3, p38, ERK1/2 or JNK, there-
fore is a more speciﬁc inhibitor of the PI3K-Akt pathway. As shown
in Fig. 3, the treatment both with wortmannin and API-2, effec-
tively suppresses the leptin-induced effects: Fig 3A: the leptin-in-
duced activation of Akt evaluated after 30 min of leptin treatment;
Fig. 3B: the leptin-induced activation of NF-kB evaluated after
30 min of leptin treatment; Fig. 3C: the up-regulation of bcl-2
and bcL-xl evaluated after 24 h of leptin treatment. Finally, and
consistently with the results obtained, wortmannin and API-2
pre-treatment suppress the leptin-induced protection from apop-
tosis (Fig. 3D) after 24 h of treatment. In all experiments performed
we tested that wortmannin or API-2 alone do not exert any effect
(data not shown).
Altogether these ﬁndings suggest that leptin acts as an anti-
apoptotic signal on human DC through the activation of PI3K-Akt
signaling pathway. Similar results were obtained by Guo et al.
demonstrating that PI3K-Akt pathway, but not the mitogen-acti-
Fig. 3. Leptin anti-apoptotic effects on DCs are mediated by the activation of the PI3K-Akt pathway. DCs were left untreated (CTR) or treated with leptin, leptin + wortmannin,
leptin + API-2 or LPS, for 30 min or 24 h. Wortmannin and API-2 treatments were performed for 30 min before leptin addition. (A, right) Akt phosphorylation was evaluated by
ﬂow cytometry after 30 min treatment. Staining proﬁle obtained with isotype-matched control Ab is overlaid for reference (gray ﬁlled shade). Results are expressed as mean
ﬂuorescence intensity (MFI). Representative results from one of four donors giving similar results are shown. (A, left) Akt phosphorylation was also evaluated after 30 min
treatment by Western blot. A representative blot from one of three donors giving similar results is shown. The results are express as fold increase over the basal level of P-Akt
in control DCs, normalized to the total Akt and actin levels. (B) Activated levels of both p50 and p65 subunits of NF-kB were analyzed after 30 min treatment. Mean
values ± S.E.M. from three different donors are shown. *P < 0.05. (C) After 24 h treatment levels of bcl-2, bcl-xL and gapdh mRNA were determined by semiquantitative RT-
PCR. For densitometric analysis, the reaction products were size-separated by electrophoresis on 1.8% agarose gel (Bio-Rad, Richmond, CA). Ethidium bromide-stained gel was
analyzed on a UV transilluminator and photographed with positive/negative 665 type ﬁlm (Polaroid, Cambridge, MA). The negative was scanned by densitometry (Bio-Rad
Multi Analyst). The bcl-2 and bcl-xL mRNA levels were normalized to mRNA gapdh levels. Representative results from one of four donors giving similar results are shown. (D)
After 24 h treatment quantitative evaluation of apoptosis was performed by ﬂow cytometry by double staining with PI and annexin V+. The histograms show means ± S.E.M.
from three different experiments. *P < 0.05.
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tective action of leptin in hippocampal neurons [20]. In contrast, in
Jurkat T cells [21] and in monocytes [17] the anti-apoptotic effect
of leptin is dependent on MAPK activation pathway.It is well established that the activation of the PI3K-Akt path-
way is instrumental to the differentiation and survival of DCs
[25] by modulating Bcl-2 levels [26,27]. Leptin has been shown
to activate the PI3K-Akt pathway in a variety of cell types and
1106 B. Mattioli et al. / FEBS Letters 583 (2009) 1102–1106the absence of functional OB-R in BM-derived DCs from db/dbmice,
results in reduced survival associated with deregulated expression
of Bcl-2 family genes, and down-regulated activity of the PI3K-Akt
pathway. Leptin signaling is therefore important for the survival
and maturation of BM-derived DCs.
Our results provide new insights on the immunoregulatory
function of leptin demonstrating its ability to promote DC survival
via PI3K-Akt pathway and Bcl-2/NF-kB activation, thus strengthen-
ing the previous proposals of a potential use of leptin as a thera-
peutic agent in several immunotherapeutic approaches.
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